Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
April 20, 2020 09:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
Navigen Announces FDA Clearance of its IND Application to Initiate First-in-Human Studies for CPT31, a Novel, D-peptide HIV Entry Inhibitor
December 10, 2019 08:00 ET
|
Navigen, Inc.
SALT LAKE CITY, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Navigen, Inc. announced today that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug application ("IND") for...
The Best Thanksgiving
November 26, 2019 17:59 ET
|
The Children's Inn at NIH
Bethesda, Maryland, Nov. 26, 2019 (GLOBE NEWSWIRE) -- One Texas family has lots to be thankful for this Thanksgiving. Their daughter, now 13, is doing well after undergoing a bone marrow...
Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators
September 29, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
Battelle Wins $102M NIAID Biodefense Research Contract
July 18, 2012 10:30 ET
|
Battelle
COLUMBUS, OH--(Marketwire - Jul 18, 2012) - Battelle has won a single-source award from the U.S. Department of Health and Human Services' National Institutes of Health for evaluation and testing...